Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

DUSA PHA Form 4 October 19,	RMACEUTICA 2006	LS INC								
FORM	ЛЛ							OMB A	PPROVAL	
	UNITED	STATES		RITIES A			E COMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to STATEMENT OF CHAN				NGES IN	BENEF	Expires: January 20 Estimated average				
Section Form 4	Section 16. SECURITIES Form 4 or							burden hours per response 0		
Form 5 obligatio may cor <i>See</i> Insta 1(b).	tinue. Section 17	(a) of the l	Public U	tility Hol	ding Cor		nge Act of 1934, t of 1935 or Section 1940	n		
(Print or Type	Responses)									
SILLI MAN D CECEEDEN			2. Issue Symbol	er Name and	l Ticker or	Trading	5. Relationship of Reporting Person(s) to Issuer			
			DUSA [DUSA		ACEUTI	CALS IN	C (Chec	k all applicabl	e)	
				of Earliest Tr Day/Year) 2006	ransaction		X Director 10% Owner X Officer (give title Other (specify below) Chairman of the Board & CEO			
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
TORONTO), A6 M5V3B2						Form filed by M Person			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities A	Acquired, Disposed of	, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	SecuritiesFBeneficially(I)Owned(I)Following(I)ReportedTransaction(s)(Instr. 3 and 4)	form: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V		(D) Price				
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities benef	ticially own	ned directly	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	tion ()	5. Number of Derivative Securities Acquired (A) Disposed of ((Instr. 3, 4, an 5)) or (D)	6. Date Exercis Expiration Dat (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and A	ecuriti
				Code V	V	(A) ((D)	Date Exercisable	Expiration Date	Title	Amou Numb Share
Class B Warrants (previously reported)	\$ 6 <u>(1)</u>	10/18/2006		J		250,000 (2)		10/18/2006	01/29/2011	Common Stock	250, <u>(2</u>

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SHULMAN D GEOFFREY C/O DUSA PHARMACEUTICALS, INC. 555 RICHMOND STREET WEST, SUITE 300 TORONTO, A6 M5V3B2	х		Chairman of the Board & CEO				

Signatures

/s/D. Geoffrey Shulman	10/19/2006			
<u>**</u> Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The conversion price of the Class B Warrants is the Canadian equivalent of U.S. \$6.00 on the date of issue, January 17, 1992, which is \$6.79 CDN.
- These warrants which were due to expire on January 29, 2007 were extended by action of the Board of Directors for an additional 4-year
 (2) term. An additional Fifty Thousand (50,000) of the 300,000 warrants previously reported will lapse if not exercised prior to January 29, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.